Abstract
With an average life expectancy of 14 months, Glioblastoma multiforme (GBM), is the most aggressive primary brain tumor. Our growing understanding of the immune system and its role in oncogenesis has helped develop cancer vaccines as a promising treatment modality against this disease. What follows is a comprehensive discussion on the history of immunotherapy and the various vaccine based therapies being developed and utilized for the treatment of malignant gliomas.
Keywords: Immunotherapy, Glioma, Vaccines, tumor cells, Glioblastoma multiforme (GBM), immunosuppression, central nervous system, CD8+ cells, immune system, HLA molecules
Current Drug Discovery Technologies
Title:Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Volume: 9 Issue: 4
Author(s): Divya Ajay, Luis Sanchez-Perez, Bryan D. Choi, Gabriel De Leon and John H. Sampson
Affiliation:
Keywords: Immunotherapy, Glioma, Vaccines, tumor cells, Glioblastoma multiforme (GBM), immunosuppression, central nervous system, CD8+ cells, immune system, HLA molecules
Abstract: With an average life expectancy of 14 months, Glioblastoma multiforme (GBM), is the most aggressive primary brain tumor. Our growing understanding of the immune system and its role in oncogenesis has helped develop cancer vaccines as a promising treatment modality against this disease. What follows is a comprehensive discussion on the history of immunotherapy and the various vaccine based therapies being developed and utilized for the treatment of malignant gliomas.
Export Options
About this article
Cite this article as:
Ajay Divya, Sanchez-Perez Luis, D. Choi Bryan, De Leon Gabriel and H. Sampson John, Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas, Current Drug Discovery Technologies 2012; 9 (4) . https://dx.doi.org/10.2174/157016312803305933
DOI https://dx.doi.org/10.2174/157016312803305933 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
Current Topics in Medicinal Chemistry Liposome-Encapsulated Photosensitizers Against Bacteria
Recent Patents on Anti-Infective Drug Discovery Erinacerins, Novel Glioma Inhibitors from <i>Hericium erinaceus</i>, Induce Apoptosis of U87 Cells through Bax/Capase-2 Pathway
Anti-Cancer Agents in Medicinal Chemistry TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Poly(ethylene glycol)-polypeptide Copolymer Micelles for Therapeutic Agent Delivery
Current Pharmaceutical Biotechnology Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design <i>In Vivo</i> Tracking of Novel SPIO-Molday ION Rhodamine-B™-Labeled Human Bone Marrow-Derived Mesenchymal Stem Cells After Lentivirus- Mediated COX-2 Silencing: A Preliminary Study
Current Gene Therapy Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies
Current Medicinal Chemistry Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Medicinal Chemistry of Drugs with Active Metabolites Following Conjugation
Mini-Reviews in Medicinal Chemistry